Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

Abstract: Provided herein are compounds, pharmaceutical compositions, and methods of use thereof, including methods of treating metabolic disorders and psychiatric disorders and diseases associated with metabolic disorders. For example, provided herein is Compound 1: or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions and methods of use thereof, including methods of treating metabolic disorders and psychiatric disorders associated with metabolic disorders.

Abstract: The present disclosure provides methods of determining the susceptibility of a dog to liver copper accumulation, comprising detecting in a biological sample obtained from the dog the presence or absence in the genome of the dog of one or more polymorphisms, and methods of treating or breeding the dog based on such determination.

Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

Abstract: During hand-held operation, configuration of an NFC/RFID Reader/Writer peripheral device in a predefined mode named “Mobile Mode with Auto-Collection”, enables recognition of a long duration (e.g. 5 second) trigger press (AKA a “Long Press”) as an enabling event prompting a change of scan behavior between single-shot scan operation and continuous scan operation. In other defined Modes of the peripheral device, other predetermined enabling events, such as the presence or absence of a predetermined external power source, prompt the change between single-shot and continuous scan operations. The Long Press and the other intuitive features enable the general user to be able to switch between various modes and to do so without requiring acquisition or use of an additional dedicated scanner with its requisite expense or inconvenience, and without requiring advanced knowledge, special access, or special resources.

Abstract: The presently disclosed subject matter relates to food products comprising oligosaccharides for an animal, such as a domestic animal or a pet. In certain embodiments, the food product can be a feline food product or a canine food product.

Abstract: During hand-held operation, configuration of an NFC/RFID Reader/Writer peripheral device in a predefined mode named “Mobile Mode with Auto-Collection”, enables recognition of a long duration (e.g. 5 second) trigger press (AKA a “Long Press”) as an enabling event prompting a change of scan behavior between single-shot scan operation and continuous scan operation. In other defined Modes of the peripheral device, other predetermined enabling events, such as the presence or absence of a predetermined external power source, prompt the change between single-shot and continuous scan operations. The Long Press and the other intuitive features enable the general user to be able to switch between various modes and to do so without requiring acquisition or use of an additional dedicated scanner with its requisite expense or inconvenience, and without requiring advanced knowledge, special access, or special resources.

Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

Abstract: During hand-held operation, configuration of an NFC/RFID Reader/Writer peripheral device in a predefined mode named “Mobile Mode with Auto-Collection”, enables recognition of a long duration (e.g. 5 second) trigger press (AKA a “Long Press”) as an enabling event prompting a change of scan behavior between single-shot scan operation and continuous scan operation. In other defined Modes of the peripheral device, other predetermined enabling events, such as the presence or absence of a predetermined external power source, prompt the change between single-shot and continuous scan operations. The Long Press and the other intuitive features enable the general user to be able to switch between various modes and to do so without requiring acquisition or use of an additional dedicated scanner with its requisite expense or inconvenience, and without requiring advanced knowledge, special access, or special resources.

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

Abstract: During hand-held operation, configuration of an NFC/RFID Reader/Writer peripheral device in a predefined mode named “Mobile Mode with Auto-Collection”, enables recognition of a long duration (e.g. 5 second) trigger press (AKA a “Long Press”) as an enabling event prompting a change of scan behavior between single-shot scan operation and continuous scan operation. In other defined Modes of the peripheral device, other predetermined enabling events, such as the presence or absence of a predetermined external power source, prompt the change between single-shot and continuous scan operations. The Long Press and the other intuitive features enable the general user to be able to switch between various modes and to do so without requiring acquisition or use of an additional dedicated scanner with its requisite expense or inconvenience, and without requiring advanced knowledge, special access, or special resources.

Abstract: The present disclosure provides methods of determining the susceptibility of a dog to liver copper accumulation, comprising detecting in a biological sample obtained from the dog the presence or absence in the genome of the dog of one or more polymorphisms, and methods of treating or breeding the dog based on such determination.

Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

Abstract: The present invention provides a method of testing a dog to determine the susceptibility of the dog to liver copper accumulation, comprising detecting in a sample the presence or absence in the genome of the dog of one or more polymorphisms selected from: (a) Chr22_3167534 (SEQ ID NO: 144), Chr22_3135144 (SEQ ID NO: 145), Chr20_55461150 (SEQ ID NO: 146), ChrX_120879711 (SEQ ID NO: 147), Chr19_6078084 (SEQ ID NO: 148), Chr15_62625262 (SEQ ID NO: 149), Chr14_39437543 (SEQ ID NO: 150), Chr15_62625024 (SEQ ID NO: 151), Chr3_86838677 (SEQ ID NO: 152), Chr24_4011833 (SEQ ID NO: 153), Chr18_60812198 (SEQ ID NO: 154), Chr10_65209946 (SEQ ID NO: 155), and the CGCCCC repeat at chromosome location 22:3135287; (b) one or more polymorphisms in linkage disequilibrium with a said polymorphism (a); and/or (c) Chr32_38904515 (SEQ ID NO: 156), Chr8_4892743 (SEQ ID NO: 157) and Chr8_4880518 (SEQ ID NO: 158).

Abstract: Disclosed are compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, Ra, R1, R2, R3, R4, R6, w and n1 are defined and described herein; compositions thereof; and methods of use thereof. These compounds are useful for treating a variety of neurological and psychiatric disorders, such as those described herein.

Abstract: Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.